VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Sponsor
Fudan University
Study ID
NCT05540951
Phase
PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate the tumor response, the radical resectability, and the patient survival.

Key Dates

First listed
Sep 15, 2022
Start date
Jun 1, 2018
Status verified
Sep 2022
Primary completion
Aug 30, 2022
Completion
Dec 30, 2022

Study Design

Enrollment
78 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: VIC
    VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
  • Active Comparator: BEV
    Bevacizumab Plus Chemotherapy

Primary Outcome Measure

progression-free survival [ Time Frame: 3 years ]

Central Contacts

Related Studies